Skip to main content

Vivos Therapeutics, Inc.

VVOS
Exchange
Nasdaq
Industry
Surgical & Medical Instruments & Apparatus
SEC CIK
0001716166

No open-market purchases or sales by Vivos Therapeutics, Inc. insiders were filed in the last 90 days; 22 institutions reported holding it in 13F filings for Q2 2026, worth $242.7K in total; no superinvestor holds it.

Q3 2023 vs. Q2 2023

How the institutions holding Vivos Therapeutics, Inc. changed between Q2 2023 and Q3 2023.

All holders in Q3 2023All holders in Q2 2023

13F holders of VVOS: Q2 2023 compared with Q3 2023
MeasureQ2 2023Q3 2023Change
Holders3128−3
Shares4.69M4.48M−216.8K (−4.6%)
Value$2.39M$860.6K−$1.53M (−64.0%)

New holders (6)

Institutions that held Vivos Therapeutics, Inc. at the end of Q3 2023 but not at the end of Q2 2023.

Institutions new to VVOS in Q3 2023
InstitutionSharesValue% of portfolio
HRT Financial LP87,697$16.0K0.00%
Wealth Enhancement Advisory Services, LLC53,334$10.2K0.00%
HighTower Advisors, LLC18,653$4.00K0.00%
UBS Group AG9,257$1.78K0.00%
Qube Research & Technologies Ltd200$380.00%
JPMorgan Chase & Co26$50.00%

Sold out (9)

Institutions that held Vivos Therapeutics, Inc. at the end of Q2 2023 and filed for Q3 2023 without it.

Institutions that sold out of VVOS in Q3 2023
InstitutionShares, Q2 2023Value, Q2 2023
Godsey & Gibb Associates92,999$47.4K
Two Sigma Investments, LP63,301$32.3K
Virtu Financial LLC50,854$26.0K
Renaissance Technologies LLC33,551$17.0K
Tower Research Capital LLC (TRC)24,573$12.5K
Two Sigma Securities, LLC12,387$6.32K
Advisor Group Holdings, Inc.1,000$510
The PNC Financial Services Group, Inc.500$255
Capital Advisors, Ltd. LLC185$0